Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 598

1.

Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients.

Fernández-Barat L, Motos A, Panigada M, Álvarez-Lerma F, Viña L, Lopez-Aladid R, Ceccato A, Bassi GL, Nicolau DP, Lopez Y, Muñoz L, Guerrero L, Soy D, Israel T, Castro P, Torres A.

Crit Care. 2019 Jul 10;23(1):251. doi: 10.1186/s13054-019-2523-5.

2.

In vitro potency of antipseudomonal β-lactams against blood and respiratory isolates of P. aeruginosa collected from US hospitals.

Almarzoky Abuhussain SS, Sutherland CA, Nicolau DP.

J Thorac Dis. 2019 May;11(5):1896-1902. doi: 10.21037/jtd.2019.05.13.

3.

Pharmacodynamics of daptomycin when prescribed in combination with other antibiotics for treatment of enterococcal bacteremia.

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP.

Int J Antimicrob Agents. 2019 Jul 5. pii: S0924-8579(19)30182-7. doi: 10.1016/j.ijantimicag.2019.07.002. [Epub ahead of print]

PMID:
31284042
4.

In vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa.

Asempa TE, Nicolau DP, Kuti JL.

Antimicrob Agents Chemother. 2019 Jul 1. pii: AAC.00997-19. doi: 10.1128/AAC.00997-19. [Epub ahead of print]

PMID:
31262769
6.

A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales.

Asempa TE, Kuti JL, Seroogy JD, Komirenko AS, Nicolau DP.

Clin Ther. 2019 May 23. pii: S0149-2918(19)30241-3. doi: 10.1016/j.clinthera.2019.04.038. [Epub ahead of print]

PMID:
31248681
7.

Ceftolozane/Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance.

Petraitis V, Petraitiene R, Naing E, Aung T, Thi WP, Kavaliauskas P, Maung BBW, Michel AO, Ricart Arbona RJ, DeRyke AC, Culshaw DL, Nicolau DP, Satlin MJ, Walsh TJ.

Antimicrob Agents Chemother. 2019 Jun 24. pii: AAC.00344-19. doi: 10.1128/AAC.00344-19. [Epub ahead of print]

PMID:
31235620
8.

In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model.

Monogue ML, Tabor-Rennie J, Abdelraouf K, Nicolau DP.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00233-19. doi: 10.1128/AAC.00233-19. Print 2019 Jul.

PMID:
31235557
9.

In vitro investigation of synergy among fosfomycin and parenteral antimicrobials against carbapenemase-producing Enterobacteriaceae.

Avery LM, Sutherland CA, Nicolau DP.

Diagn Microbiol Infect Dis. 2019 May 25. pii: S0732-8893(19)30525-5. doi: 10.1016/j.diagmicrobio.2019.05.014. [Epub ahead of print]

PMID:
31213392
10.

Carbapenem Non-susceptible Pseudomonas aeruginosa from Intensive Care Units in the United States: A Potential Role for New β-lactam Combination Agents.

Asempa TE, Nicolau DP, Kuti JL.

J Clin Microbiol. 2019 May 22. pii: JCM.00535-19. doi: 10.1128/JCM.00535-19. [Epub ahead of print]

PMID:
31118271
11.

In Vivo Pharmacodynamic Profile of Ceftibuten-Clavulanate Combination against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in the Murine Thigh Infection Model.

Abdelraouf K, Stainton SM, Nicolau DP.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00145-19. doi: 10.1128/AAC.00145-19. Print 2019 Jul.

PMID:
31061165
12.

In Vitro Pharmacodynamics of a Novel Ceftibuten-Clavulanate Combination Antibiotic against Enterobacteriaceae.

Grupper M, Stainton SM, Nicolau DP, Kuti JL.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00144-19. doi: 10.1128/AAC.00144-19. Print 2019 Jul.

PMID:
31061148
13.

In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium.

Lorenzo MP, Kidd JM, Jenkins SG, Nicolau DP, Housman ST.

J Antimicrob Chemother. 2019 Aug 1;74(8):2269-2273. doi: 10.1093/jac/dkz173.

PMID:
31050740
14.

Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.

Avery LM, Sutherland CA, Nicolau DP.

J Med Microbiol. 2019 Jun;68(6):893-897. doi: 10.1099/jmm.0.000984. Epub 2019 May 3.

PMID:
31050629
15.

Pharmacokinetics of Cefazolin and Vancomycin in Infants Undergoing Open-Heart Surgery With Cardiopulmonary Bypass.

Ingrande J, Gutierrez K, Lemmens HJ, Verma A, Nicolau DP, Sutherland CA, Ramamoorthy C.

Anesth Analg. 2019 May;128(5):935-943. doi: 10.1213/ANE.0000000000003876.

PMID:
30995208
16.

Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia: An Experimental Study.

Li Bassi G, Motos A, Fernandez-Barat L, Aguilera Xiol E, Chiurazzi C, Senussi T, Saco MA, Fuster C, Carbonara M, Bobi J, Amaro R, De Rosa F, Comaru T, Yang H, Ranzani OT, Marti JD, Rinaudo M, Comino Trinidad O, Rigol M, Bringué J, Ramirez J, Nicolau DP, Pelosi P, Antonelli M, Blasi F, Artigas A, Montgomery AB, Torres A.

Crit Care Med. 2019 Jun;47(6):e470-e477. doi: 10.1097/CCM.0000000000003724.

PMID:
30882478
17.

Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations.

Motos A, Avery LM, DeRonde KJ, Mullane EM, Kuti JL, Nicolau DP.

Int J Antimicrob Agents. 2019 May;53(5):698-702. doi: 10.1016/j.ijantimicag.2019.03.006. Epub 2019 Mar 14.

PMID:
30880231
18.

Reply to Cheng and Chuang.

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP.

Clin Infect Dis. 2019 Jan 30. doi: 10.1093/cid/ciz081. [Epub ahead of print] No abstract available.

PMID:
30715199
19.

Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing Enterobacteriaceae in the Neutropenic Murine Lung Infection Model.

Asempa TE, Motos A, Abdelraouf K, Bissantz C, Zampaloni C, Nicolau DP.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02382-18. doi: 10.1128/AAC.02382-18. Print 2019 Apr.

PMID:
30670411
20.

Development of an HPLC-MS/MS method for the determination of ceftolozane/tazobactam in bronchoalveolar lavage fluid.

Sutherland CA, Ozbal C, Nicolau DP.

Future Sci OA. 2018 Nov 15;5(1):FSO352. doi: 10.4155/fsoa-2018-0079. eCollection 2019 Jan.

21.

Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible.

Baker TM, Rogers W, Chavda KD, Westblade LF, Jenkins SG, Nicolau DP, Kreiswirth BN, Calfee DP, Satlin MJ.

Open Forum Infect Dis. 2018 Nov 19;5(12):ofy300. doi: 10.1093/ofid/ofy300. eCollection 2018 Dec.

22.
23.

Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department.

Almarzoky Abuhussain SS, Burak MA, Kohman KN, Jacknin G, Tart SB, Hobbs ALV, Adams DK, Nailor MD, Keyloun KR, Nicolau DP, Kuti JL.

BMC Health Serv Res. 2018 Dec 4;18(1):932. doi: 10.1186/s12913-018-3751-0.

24.

Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model.

Motos A, Kuti JL, Li Bassi G, Torres A, Nicolau DP.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01922-18. doi: 10.1128/AAC.01922-18. Print 2019 Feb.

PMID:
30509937
25.

Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model.

Stainton SM, Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolau DP.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01040-18. doi: 10.1128/AAC.01040-18. Print 2019 Feb.

26.

Optimizing Antibiotic Administration for Pneumonia.

Motos A, Kidd JM, Nicolau DP.

Clin Chest Med. 2018 Dec;39(4):837-852. doi: 10.1016/j.ccm.2018.08.006. Review.

PMID:
30390753
27.

In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model.

Almarzoky Abuhussain SS, Avery LM, Abdelraouf K, Nicolau DP.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01931-18. doi: 10.1128/AAC.01931-18. Print 2019 Jan.

28.

Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.

Stein GE, Smith CL, Scharmen A, Kidd JM, Cooper C, Kuti J, Mitra S, Nicolau DP, Havlichek DH.

Surg Infect (Larchmt). 2019 Jan;20(1):55-61. doi: 10.1089/sur.2018.141. Epub 2018 Oct 23.

PMID:
30351195
29.

Corrigendum to Physical Compatibility of Meropenem and Vaborbactam with Select Intravenous Drugs During Simulated Y-site Administration [Clinical Therapeutics 40 (2018) 261-269].

Kidd JM, Avery LM, Asempa TE, Nicolau DP, Kuti JL.

Clin Ther. 2018 Nov;40(11):1956. doi: 10.1016/j.clinthera.2018.09.013. Epub 2018 Oct 16. No abstract available.

PMID:
30336952
30.

Variability in Emergency Medicine Provider Decisions on Hospital Admission and Antibiotic Treatment in a Survey Study for Acute Bacterial Skin and Skin Structure Infections: Opportunities for Antimicrobial Stewardship Education.

Almarzoky Abuhussain SS, Burak MA, Adams DK, Kohman KN, Tart SB, Hobbs ALV, Jacknin G, Nailor MD, Keyloun KR, Nicolau DP, Kuti JL.

Open Forum Infect Dis. 2018 Oct 8;5(10):ofy206. doi: 10.1093/ofid/ofy206. eCollection 2018 Oct.

31.
32.

Pharmacodynamic Analysis of Daptomycin-Treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint.

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP.

Clin Infect Dis. 2018 Sep 5. doi: 10.1093/cid/ciy749. [Epub ahead of print]

PMID:
30188976
33.

Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model.

Avery LM, Abdelraouf K, Nicolau DP.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e00948-18. doi: 10.1128/AAC.00948-18. Print 2018 Nov.

34.

Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.

Avery LM, Nicolau DP.

Int J Antimicrob Agents. 2018 Nov;52(5):688-691. doi: 10.1016/j.ijantimicag.2018.07.011. Epub 2018 Jul 22.

PMID:
30044946
35.

Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model.

Kidd JM, Abdelraouf K, Asempa TE, Humphries RM, Nicolau DP.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00506-18. doi: 10.1128/AAC.00506-18. Print 2018 Oct.

36.

In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam-β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model.

Monogue ML, Giovagnoli S, Bissantz C, Zampaloni C, Nicolau DP.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e02596-17. doi: 10.1128/AAC.02596-17. Print 2018 Sep.

37.

Management of Pediatric Acute Hematogenous Osteomyelitis, Part II: A Focus on Methicillin-Resistant Staphylococcus aureus, Current and Emerging Therapies.

DeRonde KJ, Girotto JE, Nicolau DP.

Pharmacotherapy. 2018 Oct;38(10):1021-1037. doi: 10.1002/phar.2164. Epub 2018 Sep 4. Review.

PMID:
29989190
38.

Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.

Heil EL, Nicolau DP, Farkas A, Roberts JA, Thom KA.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01008-18. doi: 10.1128/AAC.01008-18. Print 2018 Sep.

39.
40.
41.

Assessment of the In Vivo Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model.

Stainton SM, Abdelraouf K, Utley L, Pucci MJ, Lister T, Nicolau DP.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00239-18. doi: 10.1128/AAC.00239-18. Print 2018 Jul.

42.

Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.

Asempa TE, Avery LM, Kidd JM, Kuti JL, Nicolau DP.

Am J Health Syst Pharm. 2018 Jul 15;75(14):1048-1056. doi: 10.2146/ajhp170839. Epub 2018 Jun 12.

PMID:
29895521
43.
44.

In Vivo Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model.

Abdelraouf K, Kim A, Krause KM, Nicolau DP.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e01074-18. doi: 10.1128/AAC.01074-18. Print 2018 Aug.

45.

Feasibility of routine synergy testing using antibiotic gradient diffusion strips in the clinical laboratory.

Avery LM, Nicolau DP.

J Antimicrob Chemother. 2018 Aug 1;73(8):2264-2265. doi: 10.1093/jac/dky165. No abstract available.

PMID:
29746659
46.

Review of antimicrobial use and considerations in the elderly population.

Giarratano A, Green SE, Nicolau DP.

Clin Interv Aging. 2018 Apr 17;13:657-667. doi: 10.2147/CIA.S133640. eCollection 2018. Review.

47.

Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations.

Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen ST, Saiman L, Nicolau DP.

Diagn Microbiol Infect Dis. 2018 Jul;91(3):294-297. doi: 10.1016/j.diagmicrobio.2018.01.020. Epub 2018 Feb 24.

PMID:
29661528
48.

Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria.

Avery LM, Nicolau DP.

Expert Opin Investig Drugs. 2018 Apr;27(4):325-338. doi: 10.1080/13543784.2018.1460354. Epub 2018 Apr 10. Review.

PMID:
29611447
50.

Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children.

Rodriguez BA, Girotto JE, Nicolau DP.

Curr Pediatr Rev. 2018;14(2):97-109. doi: 10.2174/1573396314666180308150908. Review.

PMID:
29521242

Supplemental Content

Loading ...
Support Center